Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies
Abstract Immune checkpoint inhibitors have transformed cancer therapy with the programmed cell death protein 1–programmed death‐ligand 1 axis, demonstrating substantial efficacy by targeting adaptive immunity across multiple malignancies. However, the limited clinical responses observed in a considerable proportion of...